Compounds > sch 51048
Page last updated: 2024-12-08

sch 51048

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID181442
CHEMBL ID440781
SCHEMBL ID7891903
MeSH IDM0248118

Synonyms (21)

Synonym
sch-51048
sch51048
4-{4-[4-(4-{[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazolylmethyl)oxolan-3-yl]methoxy}phenyl)piperazinyl]phenyl}-1-(ethylpropyl)-1,2,4-triazolin-5-one
4-[4-[4-[4-[[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-(1-ethylpropyl)-1,2,4-triazol-3-one
sch 51048
CHEMBL440781
4-[4-[4-[4-[[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-pentan-3-yl-1,2,4-triazol-3-one
(-)-cis-4-(4-(4-(4-(5r-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)tetrahydrofuran-3r-ylmethoxy)phenyl)piperazin-1-yl)phenyl)-2-(1-ethylpropyl)-3,4-dihydro-2h-1,2,4-triazol-3-one
161532-65-6
SCHEMBL7891903
d-threo-pentitol, 2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-(1-ethylpropyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)-
d-threo-pentitol,2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-(1-ethylpropyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)-
2,5-anhydro-1,3,4-trideoxy-2-(2,4-difluorophenyl)-4-{[4-(4-{4-[5-oxo-1-(pentan-3-yl)-1,5-dihydro-4h-1,2,4-triazol-4-yl]phenyl}piperazin-1-yl)phenoxy]methyl}-1-(1h-1,2,4-triazol-1-yl)pentitol
DTXSID10936543
2,5-anhydro-1,3,4-trideoxy-2-c-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-(1-ethylpropyl)-1,5-dihydro-5-oxo-4h-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1h-1,2,4-triazol-1-yl)-d-threo-pentitol
GLXC-26357
deshydroxy posaconazole
4-[4-[4-[4-[[(3r,5r)-5-(2,4-difluorophenyl)-5-(1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-(pentan-3-yl)-1,2,4-triazol-3-one
ZVW2AK6BVY
AKOS040749463
PD161784

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with SCH 51048 (50 or 100 mg/kg of body weight per day orally) or amphotericin B (2 mg/kg/day intraperitoneally) significantly prolonged the survival of infected mice and significantly reduced fungal titers in the kidneys (P < or = 0.05)."( SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.
Anaissie, EJ; Dignani, MC; Karyotakis, NC, 1995)		2.07

Dosage Studied

SCH 51048 was as effective as amphotericin B in improving survival, but the higher dosage was significantly (P < or = 0.0) more effective.

ExcerptRelevanceReference
" Initial studies have shown that serum concentrations determined by a microbiological assay were higher than those determined by HPLC from animals dosed with SCH 51048."( Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048).
Bartner, P; Bennett, F; Cacciapuoti, A; Ganguly, AK; Girijavallabhan, V; Hare, R; Heimark, L; Hilbert, M; Korfmacher, W; Kumari, P; Lin, CC; Liu, YT; Loebenberg, D; Lovey, R; McNamara, P; Miller, G; Nomeir, AA; Pickett, C; Pike, R; Pramanik, BN; Saksena, A; Veals, J; Wang, H, 2008)		0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID37739Compound was tested for inherent antifungal geometric minimum inhibitory concentration (GMMIC) against Aspergillus in serial dilution from 64 to 0.0313 ug/mL2002Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13
Synthesis and antifungal activity of the 2,2,5-tetrahydrofuran regioisomers of SCH 51048.
AID48248Compound was tested for inherent antifungal geometric minimum inhibitory concentration (GMMIC) against Candida albicans and Candida tropicalis in serial dilution from 64 to 0.0313 ug/mL2002Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13
Synthesis and antifungal activity of the 2,2,5-tetrahydrofuran regioisomers of SCH 51048.
AID56597Compound was tested for inherent antifungal geometric minimum inhibitory concentration (GMMIC) against Dermatophytes in serial dilution from 64 to 0.0313 ug/mL2002Bioorganic & medicinal chemistry letters, Jul-08, Volume: 12, Issue:13
Synthesis and antifungal activity of the 2,2,5-tetrahydrofuran regioisomers of SCH 51048.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (57.14)18.2507
2000's3 (42.86)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.23 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzene
[no description available]		2.0110aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.3920conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
itraconazole
[no description available]		2.0110piperazines
tetrahydrofuran
oxolane : A cyclic ether that is butane in which one hydrogen from each methyl group is substituted by an oxygen.		7.0110cyclic ether;
oxolanes;
saturated organic heteromonocyclic parent;
volatile organic compound		polar aprotic solvent
itraconazole
Itraconazole: A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.. itraconazole : An N-arylpiperazine that is cis-ketoconazole in which the imidazol-1-yl group is replaced by a 1,2,4-triazol-1-yl group and in which the actyl group attached to the piperazine moiety is replaced by a p-[(+-)1-sec-butyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]phenyl group. A potent P-glycoprotein and CYP3A4 inhibitor, it is used as an antifungal drug for the treatment of various fungal infections, including aspergillosis, blastomycosis, candidiasis, chromoblastomycosis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis.		2.3920aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		3.38701,2,3-triazole
sm 8668
Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive		1.9810
posaconazole
[no description available]		2.4420aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.3920antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Aspergillus Infection
[description not available]		02.4120
Candida Infection
[description not available]		02.4120
Aspergillosis
Infections with fungi of the genus ASPERGILLUS.		02.4120
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		02.4120
Fungal Lung Diseases
[description not available]		02.3920
Coccidioides immitis Infection
[description not available]		01.9810
Coccidioidomycosis
Infection with a fungus of the genus COCCIDIOIDES, endemic to the SOUTHWESTERN UNITED STATES. It is sometimes called valley fever but should not be confused with RIFT VALLEY FEVER. Infection is caused by inhalation of airborne, fungal particles known as arthroconidia, a form of FUNGAL SPORES. A primary form is an acute, benign, self-limited respiratory infection. A secondary form is a virulent, severe, chronic, progressive granulomatous disease with systemic involvement. It can be detected by use of COCCIDIOIDIN.		01.9810
Blastomycosis, North American
[description not available]		01.9810
Blastomycosis
A fungal infection that may appear in two forms: 1, a primary lesion characterized by the formation of a small cutaneous nodule and small nodules along the lymphatics that may heal within several months; and 2, chronic granulomatous lesions characterized by thick crusts, warty growths, and unusual vascularity and infection in the middle or upper lobes of the lung.		06.9810
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		01.9810